Evidence map›Paper›PMID 35103580›Full record

ArticleHuman vaccines & immunotherapeutics2022

Human papillomavirus infection and seroprevalence among female university students in Mexico.

Alexander Pedroza-Gonzalez, Julia Reyes-Reali, Maricela Campos-Solorzano, Eloy Moises Blancas-Diaz, Janik Adriana Tomas-Morales, Aldo Aram Hernandez-Aparicio, Daniel Montes de Oca-Samperio, Efrain Garrido, Gina Stella Garcia-Romo, Claudia Fabiola Mendez-Catala and 5 more

Open access · goldAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Alexander Pedroza-GonzalezLaboratorio de Inmunología, Unidad de Morfología y Función. Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, México.ORCID 0000-0002-8890-7656
Julia Reyes-RealiLaboratorio de Inmunología, Unidad de Morfología y Función. Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, México.
Maricela Campos-SolorzanoClínica Universitaria de Salud Integral, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, México.
Eloy Moises Blancas-DiazLaboratorio de Genética y Oncología Molecular, Laboratorio 5, Edificio A4, Carrera de Médico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, México.
Janik Adriana Tomas-MoralesLaboratorio de Inmunología, Unidad de Morfología y Función. Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, México.
Aldo Aram Hernandez-AparicioLaboratorio de Inmunología, Unidad de Morfología y Función. Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, México.
Daniel Montes de Oca-SamperioLaboratorio de Genética y Oncología Molecular, Laboratorio 5, Edificio A4, Carrera de Médico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, México.
Efrain GarridoDepartamento de Genética y Biología Molecular, CINVESTAV-IPN, Ciudad de México, México.
Gina Stella Garcia-RomoLaboratorio de Inmunología, Unidad de Morfología y Función. Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, México.ORCID 0000-0003-4819-5970
Claudia Fabiola Mendez-CatalaLaboratorio de Genética y Oncología Molecular, Laboratorio 5, Edificio A4, Carrera de Médico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, México.
Patricia Alvarez OrtizDepartamento de Genética y Biología Molecular, CINVESTAV-IPN, Ciudad de México, México.
Janet Sánchez RamosLaboratorio de Genética y Oncología Molecular, Laboratorio 5, Edificio A4, Carrera de Médico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, México.
Maria Isabel Mendoza-RamosLaboratorio de Inmunología, Unidad de Morfología y Función. Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, México.
Alberto Daniel Saucedo-CamposCarrera de Médico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, México.
Glustein Pozo-MolinaLaboratorio de Genética y Oncología Molecular, Laboratorio 5, Edificio A4, Carrera de Médico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla, México.ORCID 0000-0002-4675-4081
Autonomous University of Tlaxcala · MXCentro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional · MXUniversidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human papillomavirus (HPV) is one of the most common causes of sexually transmitted diseases, and the main etiology of cervical cancer. This study was aimed to assess type-specific cervical HPV prevalence and their association with HPV-specific antibodies in a cohort of female university students. HPV genotyping was performed by amplifying and sequencing a fragment of the L1 protein. A BLAST search was performed to identify HPV types. HPV-specific IgG antibodies were measured by ELISA in serum samples. A total of 129 women participated, with an average age of 21.75 years. The prevalence of vaginal HPV infection was 74.42%. The most predominant high-risk HPV types were 18 (13.95%), 31 (10.85%), and 16 (9.3%). We found that early age at coitarche and a higher number of sexual partners were significantly associated with a high prevalence of HPV infection. In addition to sexual behavior, we observed that the presence of serum-specific IgG antibodies against HPV can impact the prevalence of the virus. Seropositivity to HPV-16 and HPV-18 was associated with a lower prevalence of HPV-16, but not for other HPV types. Of note, there was a lower proportion of HPV-specific seropositivity in women who had the presence of the same HPV type in a cervical specimen, suggesting an immunoregulatory mechanism associated with the viral infection. In conclusion, the prevalence of HPV in university women was higher than expected and it was associated with early age of sexual debut, an increasing number of sexual partners, and a low proportion of HPV seropositivity.

Indexed as

Papillomavirus InfectionsAdultAntibodies, ViralDNA, ViralFemaleHumansImmunoglobulin GMexicoPapillomaviridaePrevalenceRisk FactorsSeroepidemiologic StudiesStudentsUniversitiesYoung AdultAntibodies, ViralDNA, ViralImmunoglobulin Gcervical cancerHuman papilloma virusMéxicoprophylactic HPV vaccinationseroprevalence

Identifiers

PMID35103580
PMCPMC8993084
OpenAlexW4210677519

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.